var data={"title":"Ganirelix: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ganirelix: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6281?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ganirelix-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ganirelix: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177286\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Orgalutran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177306\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gonadotropin Releasing Hormone Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177289\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to controlled ovarian hyperstimulation: SubQ: 250 mcg once daily during the mid-to-late phase after initiating follicle-stimulating hormone on day 2 or 3 of cycle. Treatment should be continued daily until the day of chorionic gonadotropin administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990525\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987832\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177290\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177266\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mcg/0.5 mL (0.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177252\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6265422\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer SubQ in abdomen (around navel) or upper thigh; rotate injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132600\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloves and a protective gown are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177267\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Adjunct to controlled ovarian hyperstimulation:</b> Inhibits premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3122008\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Antagon former U.S. brand name for ganirelix, but also the brand name for ranitidine in Brazil</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177259\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Ovarian hyperstimulation syndrome (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (1%), nausea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Pelvic pain (5%), vaginal hemorrhage (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, hypersensitivity reaction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177270\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ganirelix or any component of the formulation; hypersensitivity to gonadotropin-releasing hormone (GnRH) or any other GnRH analog; known or suspected pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177256\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Hypersensitivity reactions, including anaphylactoid reactions, have been reported; may occur with the first dose; use is not recommended in women with severe allergic conditions. Use with caution in women with signs and symptoms of other allergic conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: Exclude pregnancy before beginning treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Latex: The packaging may contain natural rubber latex.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced specialists: Should only be prescribed by fertility specialists.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299388\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177260\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8666&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Antigonadotropic Agents may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177271\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Studies in animals have shown evidence of fetal abnormalities, including fetal resorption, and use is contraindicated in women who are pregnant. Fetal resorption is a result of hormonal alterations and could result in fetal loss in humans. Ganirelix is used to treat infertility; pregnancy should be ruled out prior to therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265802\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ganirelix is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177264\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Ultrasound to assess follicle size</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177255\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively blocks the gonadotropin-release hormone receptors on the pituitary gonadotroph and transduction pathway. This suppresses gonadotropin secretion and luteinizing hormone secretion preventing ovulation until the follicles are of adequate size.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177269\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &lt;48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: SubQ: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:  Mean V<sub>d</sub>: Single dose: 43.7 L; Multiple dosing: 76.5 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 81.9% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to two primary metabolites (1-4 and 1-6 peptide) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: SubQ: 91.1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Single dose: 12.8 hours; Multiple dosing: 16.2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 1.1 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (75%) within 288 hours; urine (22%) within 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422232\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ganirelix Acetate Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg/0.5 mL (0.5 mL): $259.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177272\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ganilever (KR);</li>\n      <li>Ganirest (JP);</li>\n      <li>Orgalutran (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TH, TR, TW, UY, VE, VN, YE);</li>\n      <li>Orhalutran (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ganirelix acetate injection [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8666 Version 93.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F177286\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F177306\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F177289\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990525\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987832\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F177290\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F177266\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F177252\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6265422\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132600\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F177267\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3122008\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F177259\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F177270\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F177256\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299388\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F177260\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F177271\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16265802\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F177264\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F177255\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F177269\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422232\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F177272\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8666|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ganirelix-patient-drug-information\" class=\"drug drug_patient\">Ganirelix: Patient drug information</a></li></ul></div></div>","javascript":null}